Biopharmaceutical innovation and industrial developments in South Korea, Singapore and Taiwan

Australian Health Review

Volumn 33, Issue 2, 2009, Pages 245-257

  Hsieh, Chee Ruey ^a   Löfgren, Hans ^b  

^a INSTITUTE OF ECONOMICS   (Taiwan)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66749164136     PISSN: 01565788     EISSN: 14498944     Source Type: Journal    
DOI: 10.1071/AH090245     Document Type: Article

References (54)

1. World Bank. World development indicators, 2007. Available at: http://www.worldbank.org/
2. Weiss L. The myth of the powerless state: governing the economy in a global era. Cambridge: Polity Press, 1998.
3. Tsui-Auch LS. Bureaucratic rationality and nodal agency in a developmental state: the case of stateled biotechnology development in Singapore. International Sociology 2004; 19 (4): 451-77.
4. Radice H. The developmental state under global neoliberalism. Third World Quarterly 2008; 29 (6): 1153-74.
5. Amsden AH. Asia's next giant: South Korea and late industrialization. New York: Oxford University Press, 1989.
6. Wade R. Governing the market: economic theory and the role of government in East Asian industrialization. Princeton, NJ: Princeton University Press, 1990.
7. Ernst & Young. Beyond borders: global biotechnology report, 2007. Available at: http://www.ey.com/Global/assets.nsf/International/Industry_Biotechnology_Beyond_Borders_2007_Full/$file/BeyondBorders2007.pdf
8. Organisation for Economic Co-operation and Development. Biotechnology for sustainable growth and development. Paris: OECD, 2004.
9. Benner M, Löfgren H. The bio-economy and the competition state: transcending the dichotomy between coordinated and liberal market economies. New Political Science 2007; 29 (1): 77-95.
10. Löfgren H. Building the bio-economy: state steering and deliberation in biotechnology in Asia and Australia. In: Stranger M, editor. Human biotechnology and public trust: trends, perceptions and regulation. Hobart: Centre for Law and Genetics, 2007: 10-23.
11. Normile D. South Korea picks up the pieces. Science 2006; 312: 1298-9.
12. Mytelka LK. Divides and rules: the impact of new wave technologies on learning and innovation in the South. Journal of International Development 2006; 18: 861-76.
13. Wong J. From learning to creating: biotechnology and the postindustrial developmental state in Korea. Journal of East Asian Studies 2004; 4 (3): 491(27).
14. Wong J. Re-making the developmental state in Taiwan: the challenges of biotechnology. International Political Science Review 2005; 26 (2): 169-91.
15. Feldbaum H, Patel P, Sondorp E, Lee K. Global health and national security: the need for critical engagement. Medicine, Conflict & Survival 2006; 22 (3): 192-8.
16. Hobday M. East versus Southeast Asian innovation systems: comparing OEM- and TNC-led growth in electronics. In: Kim L, Nelson R, editors. Technology, learning and innovation: experiences of newly industrializing economies. New York: Cambridge University Press, 2000: 129-69.
17. Chaudhuri S. The WTO and India's pharmaceuticals industry: patent protection, TRIPS, and developing countries. New Delhi: Oxford University Press, 2005.
18. Uttam J. Korea's new techno-scientific state: mapping a strategic change in the 'developmental state'. China Report 2006; 42 (3): 257-68.
19. Cooke P. Growth cultures: the global bioeconomy and its bioregions. London: Routledge, 2007.
20. Dickins A. Vital issues and theoretical challenges: international political economy and the global bioeconomy. GBRG Working Papers No 7. Norwich: Global Biopolitics Research Group, University of East Anglia, 2006.
21. Sloan FA, Hsieh C-R. Conclusion and policy implications. In: Sloan FA, Hsieh C-R, editors. Pharmaceutical innovation: incentives, competition, and cost-benefit analysis in international perspective. New York: Cambridge University Press, 2007: 262-77.
22. Grabowski HG, Wang YR. The quantity and quality of worldwide new drug introductions, 1982-2003. Health Affairs (Millwood) 2006; 25 (2): 452-60.
23. Comanor WS. The economics of research and development in the pharmaceutical industry. In: Sloan FA, Hsieh C-R, editors. Pharmaceutical innovation: incentives, competition, and cost-benefit analysis in international perspective. Cambridge: Cambridge University Press, 2007: 54-72.
24. Garnier J-P. Rebuilding the R&D engine in big pharma. Harvard Business Review 2008; 86 (5): 68-76.
25. Danzon PM, Nicholson S, Pereira NS. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances. Journal of Health Economics 2005; 24: 317-39.
26. Mittra J. Life Science Innovation and the restructuring of the pharmaceutical industry: mergers, acquisitions and strategic alliance behaviour of large firms. Technology Analysis & Strategic Management 2007; 19(3): 279-301.
27. Anonymous. Pharma firms for collaborations. The Hindu 2009; 3 February: 4.
28. Reinhardt UE. The pharmaceutical sector in health care. In: Sloan FA, Hsieh C-R, editors. Pharmaceutical innovation: incentives, competition, and costbenefit analysis in international perspective. New York: Cambridge University Press, 2007: 25-53.
29. Frew SE, Kettler HE, Singer PA. The Indian and Chinese health biotechnology industries: potential champions of global health? Health Affairs (Millwood) 2008; 27 (4): 1029-41.
30. Roumeliotis G. India set to overtake Italy in API production: DrugResearcher.com 2006; 10 May. Available at: http://www.drugresearcher.com/news/ng.asp?id=67610
31. Congressional Budget Office. Research and development in the pharmaceutical industry. Washington, DC: 2006.
32. Murphy KM, Topel RH. The economic value of medical research. In: Murphy KM, Topel RH, editors. Measuring the gains from medical research: an economic approach. Chicago: University of Chicago Press, 2003: 41-73.
33. Sloan FA, Hsieh C-R. Effects of incentives on pharmaceutical innovation. In: Sloan FA, Kasper H, editors. Incentives and choice in health care. Cambridge, Mass: MIT Press, 2008: 227-62.
34. Cockburn IM, Henderson RM. Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. Journal of Industrial Economics 1998; 46 (2): 157-82.
35. Tsuei SE. The role of the Asia-Pacific region in global drug development strategy. Drug Information Journal 2009; 43 (1): 35-40.
36. Azoulay P. Capturing knowledge within and across firm boundaries: evidence from clinical development. American Economics Review 2004; 94 (5): 1591-612.
37. Agency for Science Technology and Research. A*STAR Yearbook 2007/08. Singapore, 2008. Available at: http://www.a-star.edu.sg/a_star/412-A-STARYEARBOOK-2007-2008
38. Yeoh K-C. Singapore's biomedical sciences landscape. J Commer Biotechnol 2007; 14 (2): 141-8.
39. Normile D. Biomedical research: an Asian Tiger's bold experiment. Science 2007; 316: 38-41.
40. Ministry of Economic Affairs. Biotechnology industry in Taiwan [Chinese]. Taipei: MOEA, 2008.
41. Walsh G. Biopharmaceutical benchmarks 2006. Nature Biotechnology 2006; 24: 769-76.
42. Philipson TJ, Sun E. Is the Food and Drug Administration safe and effective? Journal of Economic Perspectives 2008; 22 (1): 85-102.
43. Cockburn IM. Pharmaceuticals. In: Macher JT, Mowery DC, editors. Innovation in global industries: US firms competing in a new world Washington, DC: National Academies Press, 2008: 207-30.
44. National Science Council (Taiwan). Indicators of science and technology. Taipei: NSC, 2004.
45. Sun C-L. Innovation strategies of Taiwan's biotechnology industry [Chinese]. Review of Taiwan Economics 2003; 9 (2): 1-22.
46. US, National Institutes of Health ClinicalTrials.gov, 2009. Available at: http://clinicaltrials.gov
47. Australian Bureau of Statistics. Research and experimental development, all sector summary, Australia, 2006-07. Canberra: ABS, 2008. (ABS Cat. No. 8112.0.)
48. Finegold D, Wong P-K, Cheah T-C. Adapting a foreign direct investment strategy to the knowledge economy: the case of Singapore's emerging biotechnology cluster. European Planning Studies 2004; 12 (7): 921-41.
49. Gin BS. A global biomedical sciences hub. Drug Discovery Today 2005; 10 (17): 1134-7.
50. Food and Drug Administration. Approval letter for NDA 21-158. Rockville, MD: FDA, 2003.
51. Yang BM, Bae EY, Kim J. Economic evaluation and pharmaceutical reimbursement reform in South Korea's national health insurance. Health Affairs 2008; 27 (1): 179-87.
52. Hsieh C-R. Pharmaceutical policy in Taiwan. In: Eggleston K, editor. Prescribing cultures and pharmaceutical policy in the Asia-Pacific. Brookings Institution Press, (forthcoming) 2009.
53. Drummond MF. Using economic evaluation in reimbursement decisions for health technologies: lessons from international experience. In: Sloan FA, Hsieh C-R, editors. Pharmaceutical innovation: incentives, competition, and cost-benefit analysis in international perspective. New York: Cambridge University Press, 2008: 215-25.
54. Löfgren H. India's drug multinationals: growth strategies and global industry dynamics. In: Löfgren H, Sarangi P, editors. The politics and culture of globalisation: India and Australia. New Delhi: Social Science Press, 2009: 181-98.